The future of the pharmaceutical sciences and graduate education: recommendations from the AACP Graduate Education Special Interest Group
- PMID: 23716757
- PMCID: PMC3663643
- DOI: 10.5688/ajpe774S2
The future of the pharmaceutical sciences and graduate education: recommendations from the AACP Graduate Education Special Interest Group
Abstract
Despite pharma's recent sea change in approach to drug discovery and development, U.S. pharmaceutical sciences graduate programs are currently maintaining traditional methods for master's and doctoral student education. The literature on graduate education in the biomedical sciences has long been advocating educating students to hone soft skills like communication and teamwork, in addition to maintaining excellent basic skills in research. However, recommendations to date have not taken into account the future trends in the pharmaceutical industry. The AACP Graduate Education Special Interest Group has completed a literature survey of the trends in the pharmaceutical industry and graduate education in order to determine whether our graduate programs are strategically positioned to prepare our graduates for successful careers in the next few decades. We recommend that our pharmaceutical sciences graduate programs take a proactive leadership role in meeting the needs of our future graduates and employers. Our graduate programs should bring to education the innovation and collaboration that our industry also requires to be successful and relevant in this century.
Keywords: career; education; future; graduate; higher education; jobs; pharmaceutical industry; pharmaceutical sciences; pharmacy; preparation; skills.
References
-
- PricewaterhouseCoopers. Pharma 2020: Virtual R&D which path will you take? Pharma 2020: Virtual 2020. 2008:1.
-
- Craven R. The risky business of drug development in neurology. 2011;2013;10(2):116–117. http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2811%2970.... Accessed January 16. - PubMed
-
- Talaga P. The future of pharmaceutical R&D: somewhere between open and reverse innovation? Future Med. Chem. 2010;2(9):1399. - PubMed
-
- Kessel M. The problems with today's pharmaceutical business-an outsider's view. Nat Biotechnol. 2011;29(1):27. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
